Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.

The Journal of rheumatology - 1 May 2012

Ramírez Julio, Fernández-Sueiro José Luis, López-Mejías Raquel, Montilla Carlos, Arias Maite, Moll Concepción, Alsina Mercé, Sanmarti Raimon, Lozano Francisco, Cañete Juan D

Abstract excerpt

OBJECTIVE: The efficacy of antibody-based biological therapies currently used in psoriatic arthritis (PsA) depends not only on their blocking effect on the targeted molecule but also on their binding affinity to genetically defined variants of cell-surface Fc-γ receptors. Our objective was to assess the potential influence of functionally relevant FCGR2A/CD32A (H131R) and FCGR3A/CD16A (V158F) genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Psoriatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Etanercept

Share to Immunoglobulin G

Share to Longitudinal Studies

Share to Methotrexate

Share to Receptors, IgG

Share to Receptors, Tumor Necrosis Factor

Source

Identifiers

PMID: 22467926
DOI: 10.3899/jrheum.110980

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.PMID 22467926Read ↗

FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.Semantic proximity Read ↗

Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.Semantic proximity Read ↗

The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.Semantic proximity Read ↗

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.Semantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?Semantic proximity Read ↗

TNFα rs1800629 Polymorphism and Response to Anti-TNFα Treatment in Behçet Syndrome: Data from an Italian Cohort StudySemantic proximity Read ↗

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.Semantic proximity Read ↗

Polymorphisms of CD16A and CD32 Fcγ receptors and circulating immune complexes in Ménière's disease: a case-control study.Semantic proximity Read ↗

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.Semantic proximity Read ↗

Simple genotyping of functional polymorphisms of the human immunoglobulin G receptors CD16A and CD32A: a reference cell panel.Semantic proximity Read ↗

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.